Creative Planning - KARYOPHARM THERAPEUTICS INC ownership

KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 152 filers reported holding KARYOPHARM THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 1.29 and the average weighting 0.5%.

Quarter-by-quarter ownership
Creative Planning ownership history of KARYOPHARM THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$15,544
-25.1%
11,6000.0%0.00%
Q2 2023$20,764
-54.0%
11,6000.0%0.00%
Q1 2023$45,124
+14.4%
11,6000.0%0.00%
Q4 2022$39,440
-37.4%
11,6000.0%0.00%
Q3 2022$63,000
+21.2%
11,6000.0%0.00%
Q2 2022$52,000
-46.4%
11,600
-11.5%
0.00%
Q1 2022$97,000
+15.5%
13,1000.0%0.00%
Q4 2021$84,000
-10.6%
13,100
-18.6%
0.00%
Q3 2021$94,000
-43.4%
16,1000.0%0.00%
Q2 2021$166,000
-54.6%
16,100
-53.7%
0.00%
-100.0%
Q1 2021$366,000
-55.5%
34,792
-34.5%
0.00%
-50.0%
Q4 2020$822,000
+218.6%
53,117
+200.6%
0.00%
+100.0%
Q3 2020$258,000
-86.9%
17,672
-91.3%
0.00%
-83.3%
Q3 2019$1,962,000
+4260.0%
203,950
+3979.0%
0.01%
Q2 2017$45,000
-29.7%
5,0000.0%0.00%
Q1 2017$64,000
+18.5%
5,000
-12.3%
0.00%
Q4 2016$54,000
+10.2%
5,700
+14.0%
0.00%
Q3 2016$49,000
+44.1%
5,0000.0%0.00%
Q2 2016$34,000
-24.4%
5,0000.0%0.00%
Q1 2016$45,000
-32.8%
5,000
-0.5%
0.00%
-100.0%
Q4 2015$67,000
+26.4%
5,0250.0%0.00%
Q3 2015$53,000
+5200.0%
5,025
+20000.0%
0.00%
Q1 2015$1,000
-95.0%
25
-95.2%
0.00%
Q4 2014$20,0005250.00%
Other shareholders
KARYOPHARM THERAPEUTICS INC shareholders Q4 2019
NameSharesValueWeighting ↓
COMMODORE CAPITAL LP 3,561,052$26,245,0005.86%
Palo Alto Investors LP 5,621,533$41,431,0003.20%
Iron Triangle Partners LP 2,000,000$14,740,0001.75%
Altium Capital Management LP 645,000$4,754,0001.59%
Birchview Capital, LP 269,332$1,985,0001.43%
Rubric Capital Management LP 3,607,443$26,587,0000.96%
Lombard Odier Asset Management (Switzerland) SA 776,053$5,720,0000.45%
RICE HALL JAMES & ASSOCIATES, LLC 1,344,929$9,912,0000.40%
Golden State Equity Partners 41,850$308,0000.16%
Hennion & Walsh Asset Management, Inc. 385,837$2,844,0000.15%
View complete list of KARYOPHARM THERAPEUTICS INC shareholders